Exhibit R-2, RDT&E Budget Item Justification: PB 2020 Defense Advanced Research Projects Agency

Appropriation/Budget Activity R-1 Program Element (Number/Name)

0400: Research, Development, Test & Evaluation, Defense-Wide I BA 2:

PE 0602115E I BIOMEDICAL TECHNOLOGY

Date: March 2019

Applied Research

| COST (\$ in Millions)           | Prior<br>Years | FY 2018 | FY 2019 | FY 2020<br>Base | FY 2020<br>OCO | FY 2020<br>Total | FY 2021 | FY 2022 | FY 2023 | FY 2024 | Cost To<br>Complete | Total<br>Cost |
|---------------------------------|----------------|---------|---------|-----------------|----------------|------------------|---------|---------|---------|---------|---------------------|---------------|
| Total Program Element           | -              | 88.962  | 101.300 | 97.771          | -              | 97.771           | 123.570 | 120.783 | 122.687 | 134.997 | -                   | -             |
| BT-01: BIOMEDICAL<br>TECHNOLOGY | -              | 88.962  | 101.300 | 97.771          | -              | 97.771           | 123.570 | 120.783 | 122.687 | 134.997 | -                   | -             |

#### A. Mission Description and Budget Item Justification

This Biomedical Technology Program Element focuses on applied research for medical related technology, information, processes, materials, systems, and devices. Successful battlefield medical and neural interface technologies developed within this Program Element address a broad range of DoD challenges to ensure warfighter readiness, including both resilience to infectious disease and neurotechnology for improved warfighter performance. To maintain warfighter health, battlefield medical technologies research in this project will investigate disease forecasting, detection, and therapeutic response. Example programs include a predictive platform for forecasting disease outbreak, identification of early infection biomarkers to diagnose and prevent widespread infection in-theater, new methods to rapidly develop medical countermeasures in response to an emerging biothreat, and in-theater manufacturing capabilities for field-relevant pharmaceuticals to reduce the logistical burden and infrastructure requirements. To improve warfighter performance, this project will develop new neural architectures and data processing algorithms to interface the nervous system with multiple devices, enabling control of robotic prosthetic-limb technology. Additionally, advanced evidence-based techniques will be developed to supplement warfighter healthcare and the diagnosis of post-traumatic stress disorder (PTSD) and traumatic brain injury (TBI).

| B. Program Change Summary (\$ in Millions)            | FY 2018 | FY 2019 | FY 2020 Base | FY 2020 OCO | FY 2020 Total |
|---|---------|---------|--------------|-------------|---------------|
| Previous President's Budget                           | 109.360 | 101.300 | 130.831      | -           | 130.831       |
| Current President's Budget                            | 88.962  | 101.300 | 97.771       | -           | 97.771        |
| Total Adjustments                                     | -20.398 | 0.000   | -33.060      | -           | -33.060       |
| <ul> <li>Congressional General Reductions</li> </ul>  | -15.000 | 0.000   |              |             |               |
| <ul> <li>Congressional Directed Reductions</li> </ul> | 0.000   | 0.000   |              |             |               |
| <ul> <li>Congressional Rescissions</li> </ul>         | 0.000   | 0.000   |              |             |               |
| <ul> <li>Congressional Adds</li> </ul>                | 0.000   | 0.000   |              |             |               |
| <ul> <li>Congressional Directed Transfers</li> </ul>  | 0.000   | 0.000   |              |             |               |
| Reprogrammings  | -1.398  | 0.000   |              |             |               |
| SBIR/STTR Transfer                                    | -4.000  | 0.000   |              |             |               |
| <ul> <li>TotalOtherAdjustments</li> </ul>             | -       | -       | -33.060      | -           | -33.060       |

#### **Change Summary Explanation**

FY 2018: Decrease reflects Congressional reduction, SBIR/STTR transfer and reprogrammings.

FY 2019: N/A

FY 2020: Decrease reflects completion of the Neuro-Adaptive Technology and Enhanced Monitoring of Health and Disease programs in FY 2019.

PE 0602115E: BIOMEDICAL TECHNOLOGY Defense Advanced Research Projects Agency

**UNCLASSIFIED** 

Page 1 of 8 R-1 Line #9

| Exhibit R-2, RDT&E Budget Item Justification: PB 2020 Defense Advance   | ed Research Projects Agency   | Date: M | larch 2019 |         |
|---|---|---------|------------|---------|
| Appropriation/Budget Activity 0400: Research, Development, Test & Evaluation, Defense-Wide I BA 2: Applied Research   | R-1 Program Element (Number/Name) PE 0602115E I BIOMEDICAL TECHNOLOGY   |         |            |         |
| C. Accomplishments/Planned Programs (\$ in Millions)  |   | FY 2018 | FY 2019    | FY 2020 |
| Title: Restoration of Auditory and Visual Function After Injury*  |   | 15.900  | 16.485     | 13.676  |
| <b>Description:</b> *Formerly Performance Optimization in Complex Environment   | ts  |         |            |         |
| The Restoration of Auditory and Visual Function After Injury program is developed injury to the auditory and visual systems of military personnel. Rest of sensing and actuation to improve outcomes and how biofeedback over time developed through this program will provide foundational neural interface testituational awareness, and enhancing cognitive and physical effectiveness.  | search is also focusing on understanding various forms me can alter human brain function. Technologies  |         |            |         |
| FY 2019 Plans:  - Validate system designs and safety methods against standard regulatory  - Demonstrate large-scale neural read and write capabilities using a fully in  - Collect data for the development and refinement of neural decoding and e  - Prepare regulatory documents for Food and Drug Administration approval   | tegrated system. encoding algorithms.   |         |            |         |
| <ul> <li>FY 2020 Plans:</li> <li>Validate system designs for prototyping and manufacture.</li> <li>Harden size, weight, and power of complete integrated system.</li> <li>Perform in vivo demonstration of the fully integrated input-output platform.</li> </ul>   |   |         |            |         |
| FY 2019 to FY 2020 Increase/Decrease Statement: The FY 2020 decrease reflects completion of research activities to conduct  | final system validation and demonstration.  |         |            |         |
| Title: Neural Signal Interfaces and Applications (NSIA)   |   | 8.140   | 15.895     | 19.125  |
| <b>Description:</b> As part of their daily duties, many military personnel must han systems. These tasks could be made less difficult with advanced neurotech require invasive surgery to implement. The Neural Signal Interfaces and Appendix neurotechnologies able to interface with the nervous system with high resoluted recent advances to transduce neural signals through tissue. Resulting tech interfaces for improved workload balance between man and machine. | nnology platforms, but all such devices currently oplications (NSIA) program will develop non-invasive ution and precision without surgery. NSIA will utilize |         |            |         |
| FY 2019 Plans: - Finalize system level design to optimize power usage Engineer prototypes of neural interface subcomponents and neural transc Assess neural read and write subcomponents and neural transducers in v  |   |         |            |         |

PE 0602115E: *BIOMEDICAL TECHNOLOGY* Defense Advanced Research Projects Agency

UNCLASSIFIED Page 2 of 8

| Exhibit R-2, RDT&E Budget Item Justification: PB 2020 Defense Advance   | ed Research Projects Agency   | Date: N | larch 2019 |         |
|---|---|---------|------------|---------|
| Appropriation/Budget Activity 0400: Research, Development, Test & Evaluation, Defense-Wide I BA 2: Applied Research   | R-1 Program Element (Number/Name) PE 0602115E I BIOMEDICAL TECHNOLOGY   | ,       |            |         |
| C. Accomplishments/Planned Programs (\$ in Millions)  - Verify and validate the safety, resolution, and stability of subcomponents.   |   | FY 2018 | FY 2019    | FY 2020 |
| <ul> <li>FY 2020 Plans:</li> <li>Integrate neural read and write subcomponents.</li> <li>Optimize neural transducer delivery plan.</li> <li>Initiate experiments toward achieving regulatory approval for clinical studies</li> </ul>   | 9S.   |         |            |         |
| FY 2019 to FY 2020 Increase/Decrease Statement: The FY 2020 increase reflects integration of all subcomponents into final promodels.  | ototype device as well as demonstration in animal   |         |            |         |
| Title: Pandemic Prevention  |   | 17.100  | 24.985     | 24.450  |
| <b>Description:</b> Military personnel are deployed all over the world for traditional response to emerging or re-emerging disease outbreaks with pandemic pote effective countermeasures to protect its deployed forces and maintain warfig focusing on novel methods to rapidly accelerate countermeasure discovery, seeks to advance and integrate newly developed approaches including bioin nucleic acid-based vaccines and to address technology bottlenecks associated development. Additional research will investigate new methods improving the therapeutics. Pandemic Prevention will enable an integrated therapeutic development to prevent disease outbreaks. | ential (e.g., Ebola). In both instances, the DoD needs the readiness. The Pandemic Prevention program is pre-clinical testing, and manufacturing. This program informatics assessment of genetic sequencing and ted with each stage of medical countermeasure me manufacturability, distribution, and delivery of novel |         |            |         |
| <ul> <li>FY 2019 Plans:</li> <li>Demonstrate the ability to rapidly discover and mature antibodies against very methods in animal models.</li> <li>Demonstrate protection from pathogen challenge in animal models.</li> <li>Conduct, in under 90 days, preliminary demonstration of integrated technological entibody to provide protection against viral challenge in animal models.</li> <li>Initiate development and testing of nucleic acid constructs to encode for methods.</li> </ul>   | ologies identifying, maturing, and delivering a genedels.   |         |            |         |
| <ul> <li>FY 2020 Plans:</li> <li>Investigate the kinetic profile of gene-encoded antibodies in large animal new Conduct, in under 60 days, a demonstration of integrated technologies ide antibody to provide protection against viral challenge in animal models.</li> <li>Demonstrate, in less than 20 days, the ability to identify a highly potent and File an Investigational New Drug (IND) application with the Food and Drug</li> </ul>   | ntifying, maturing, and delivering a gene-encoded tibody, targeting a viral pathogen.   |         |            |         |

PE 0602115E: *BIOMEDICAL TECHNOLOGY* Defense Advanced Research Projects Agency

UNCLASSIFIED
Page 3 of 8

|  | JNCLASSIFIED   |         |            |         |
|--|--|---------|------------|---------|
| Exhibit R-2, RDT&E Budget Item Justification: PB 2020 Defense Advance  | ed Research Projects Agency  | Date: M | larch 2019 |         |
| Appropriation/Budget Activity 0400: Research, Development, Test & Evaluation, Defense-Wide I BA 2: Applied Research  | R-1 Program Element (Number/Name) PE 0602115E I BIOMEDICAL TECHNOLOGY  | 1       |            |         |
| C. Accomplishments/Planned Programs (\$ in Millions)   |  | FY 2018 | FY 2019    | FY 2020 |
| <ul> <li>Initiate a Phase I human clinical safety study of a gene-encoded antibody.</li> <li>Initiate IND enabling studies for a nucleic acid construct encoding multiple</li> </ul>   |  |         |            |         |
| FY 2019 to FY 2020 Increase/Decrease Statement: The FY 2020 decrease reflects minor program repricing.   |  |         |            |         |
| Title: Forensic Indicators of Threat Exposure (FITE)   |  | 4.750   | 13.995     | 14.404  |
| <b>Description:</b> Based on initial research conducted under the Enhanced Month Indicators of Threat Exposure (FITE) program is developing a field-deployable history to Weapons of Mass Destruction (WMD) and WMD precursors. FITE signatures in an individual's genome caused by specific exposures. The protechnology capable of performing forensic analysis using epigenetic informal and when it occurred. This novel capability could serve as a field-forward for biological, radiological, and nuclear (CBRN) threat detection and response. | ble resource for indicators of an individual's exposure will investigate the ability to characterize epigenetic orgam will create the framework for modular tion to provide high specificity of the type of exposure |         |            |         |
| <ul> <li>FY 2019 Plans:</li> <li>Identify exposure-specific epigenetic marks that reflect WMD or WMD predefect of the control of the control of the forensic and diagnostics signature.</li> <li>Validate sensitivity and specificity of the forensic and diagnostics signature.</li> <li>Develop a platform prototype to integrate multiple molecular analysis technologies.</li> <li>Initiate research to understand connections between genotype and phenomenance.</li> </ul>   | the complex epigenetic marks associated with each es when combined with detection algorithms.  Iniques and perform forensic and diagnostic   |         |            |         |
| <ul> <li>FY 2020 Plans:</li> <li>Generate epigenetic signatures that reveal temporal resolution of exposure events.</li> <li>Refine bioinformatics algorithms for increased sensitivity and specificity of</li> <li>Perform pressure tests to assess the ability to distinguish viral from bacter</li> <li>Select molecular analysis methods for integration into the deployable platf</li> <li>Finalize selection of module components and complete system design for</li> </ul>  | e events from WMD or WMD precursor exposure the epigenetic signatures. ial signatures in clinical samples. orm.  |         |            |         |
| FY 2019 to FY 2020 Increase/Decrease Statement: The FY 2020 increase reflects minor program repricing.   |  |         |            |         |
| Title: Prosthetic Hand Proprioception & Touch Interfaces (HAPTIX)  |  | 15.074  | 14.985     | 9.149   |

PE 0602115E: *BIOMEDICAL TECHNOLOGY* Defense Advanced Research Projects Agency

**UNCLASSIFIED** 

Page 4 of 8 R-1 Line #9

|   | NCLASSIFIED  |         |            |         |
|---|--|---------|------------|---------|
| Exhibit R-2, RDT&E Budget Item Justification: PB 2020 Defense Advance   | d Research Projects Agency   | Date: N | larch 2019 |         |
| Appropriation/Budget Activity 0400: Research, Development, Test & Evaluation, Defense-Wide I BA 2: Applied Research   | R-1 Program Element (Number/Name) PE 0602115E / BIOMEDICAL TECHNOLOGY  |         |            |         |
| C. Accomplishments/Planned Programs (\$ in Millions)  |  | FY 2018 | FY 2019    | FY 2020 |
| <b>Description:</b> Wounded warriors often suffer from neural injury due to spinal amputated limbs get limited benefit from recent advances in prosthetic-limb to the limb is low-performance and unreliable. Through investments in the DAF program, novel interface systems have been developed that overcome these patient. The goal of the Prosthetic Hand Proprioception & Touch Interfaces (motor & sensory) peripheral nerve implant for controlling and sensing advant transition, the HAPTIX program will create and transition clinically relevant te from single or multiple limb loss. Research in this area will also address simil such as the spinal cord. The anticipated transition partner is the Army. | echnology because the user interface for controlling RPA Reliable Neural-Interface Technology (RE-NET) issues and are designed to last for the lifetime of the HAPTIX) program is to create the first bi-directional ced prosthetic limb systems. With a strong focus on chnology in support of wounded warriors suffering |         |            |         |
| <ul> <li>FY 2019 Plans:</li> <li>Obtain regulatory approval for HAPTIX technology.</li> <li>Conduct novel outcome metric testing on HAPTIX amputee participants.</li> <li>Initiate take-home studies of the HAPTIX system.</li> <li>Initiate algorithm development, hardware manufacturing, and system integral.</li> </ul>   | ration for spinal cord injury.   |         |            |         |
| FY 2020 Plans:  - Complete take-home studies utilizing HAPTIX technology and sensorized processes and perform proof of concept of a percutaneous  |  |         |            |         |
| FY 2019 to FY 2020 Increase/Decrease Statement: The FY 2020 decrease reflects completion of take-home studies.  |  |         |            |         |
| Title: Improved Personnel Placement (IPP)   |  | -       | -          | 16.967  |
| <b>Description:</b> Building upon work initiated under the Forensic Indicators of The Personnel Placement (IPP) program will aim to improve force lethality and own specialized military positions in order to maximize performance and minimized genotype and phenotype to identify unique physical, cognitive, and behavioral program will develop technology to sense real time gene activity associated withis information to provide warfighters with training options to maximize their aptitude will enable placement choices that facilitate readiness and resilience   | rermatch by identifying and training candidates for attrition. IPP will study the relationships between all traits associated with elite military specialties. The with those identified performance traits and leverage potential. Maximizing an individual's biological  |         |            |         |
| FY 2020 Plans:  - Compare attributes of specialized warfighters to identify biomarkers associ  - Design in silico and in vitro testbeds to emulate extreme training or perform  |  |         |            |         |

PE 0602115E: *BIOMEDICAL TECHNOLOGY* Defense Advanced Research Projects Agency

UNCLASSIFIED
Page 5 of 8

|  | JNCLASSIFIED  |         |           |         |  |
|--|---|---------|-----------|---------|--|
| Exhibit R-2, RDT&E Budget Item Justification: PB 2020 Defense Advance  | ed Research Projects Agency   | Date: M | arch 2019 |         |  |
| Appropriation/Budget Activity 0400: Research, Development, Test & Evaluation, Defense-Wide I BA 2: Applied Research  R-1 Program Element (Number/Name) PE 0602115E I BIOMEDICAL TECHNOLOGY   |   |         |           |         |  |
| C. Accomplishments/Planned Programs (\$ in Millions)   | [   | FY 2018 | FY 2019   | FY 2020 |  |
| <ul> <li>Build data analysis approaches that can integrate proteomic, genomic, and</li> <li>Develop initial real-time indicators for gene expression.</li> </ul>   | d epigenomic results to characterize elite performers.  |         |           |         |  |
| FY 2019 to FY 2020 Increase/Decrease Statement: The FY 2020 increase reflects program initiation.  |   |         |           |         |  |
| Title: Neuro-Adaptive Technology   |   | 12.210  | 10.955    | -       |  |
| <b>Description:</b> The Neuro-Adaptive Technology program is exploring and devand monitoring of neural activity. One shortcoming of today's brain functionatime correlation data that links neural function to human activity and behavior as well as the underlying mechanisms that link brain and behavior is a critical military personnel suffering from a variety of brain disorders. Efforts under the in post-traumatic stress disorder (PTSD), traumatic brain injury (TBI), depressameliorate these disorders. The objective for this program is to develop new the relationship between human behavioral expression and neural function a tools will allow for an improved understanding of how the brain regulates between-therapies for treating neuropsychiatric and neurological disorders in material program include devices for real-time detection of brain activity during operal activity and behavior, and statistical models that correlate neural activity with | al mapping technologies is the inability to obtain real- ir. Understanding the structure-function relationship al step in providing real-time, closed-loop therapies for his program examine the networks of neurons involved ssion, and anxiety as well as determine how to best v hardware and modeling tools to better discriminate and to provide relief through novel devices. These havior and will enable new, disorder-specific, dynamic hilitary personnel. Technologies of interest under this tional tasks, time synchronized acquisition of brain |         |           |         |  |
| FY 2019 Plans:  - Utilize clinical data to further refine biomarkers, computational models, and psychiatric or neurologic conditions.  - Integrate approaches targeting psychiatric or neurologic conditions with computational models.  - Demonstrate use of the prototype neural device in a clinical setting to reduthrough real-time, closed-loop, biomarker-driven stimulation.   | omplementary biomarkers, neural targets, and  |         |           |         |  |
| FY 2019 to FY 2020 Increase/Decrease Statement: The FY 2020 decrease reflects program completion.  |   |         |           |         |  |
| Title: Enhanced Monitoring of Health and Disease   |   | 5.460   | 4.000     | -       |  |
| <b>Description:</b> The Enhanced Monitoring of Health and Disease program is in leveraging advanced data collection methods and prognostic capabilities to pulsease from the individual to the population scale. While new technology pulsease from the individual to the population scale.  | predict changes in health and spread of infectious  |         |           |         |  |

PE 0602115E: *BIOMEDICAL TECHNOLOGY* Defense Advanced Research Projects Agency

UNCLASSIFIED Page 6 of 8

| •  | JNCLA55IFIED  |         |           |         |
|--|---|---------|-----------|---------|
| Exhibit R-2, RDT&E Budget Item Justification: PB 2020 Defense Advance  | ed Research Projects Agency   | Date: M | arch 2019 |         |
| Appropriation/Budget Activity 0400: Research, Development, Test & Evaluation, Defense-Wide I BA 2: Applied Research  | R-1 Program Element (Number/Name) PE 0602115E I BIOMEDICAL TECHNOLOGY   |         |           |         |
| C. Accomplishments/Planned Programs (\$ in Millions)   |   | FY 2018 | FY 2019   | FY 2020 |
| illness and disease, there is a need for predictive and pre-emptive technology prior to its obvious need, such as in a barracks or in a confined environment investigate new methods for the collection and detection of multiplexed biology ultimate integration of vast personalized data into the clinical care information will develop new approaches to integrate multi-source data streams to creat spread. Technologies developed in this program will enable clinically action awareness of symptoms, and extend infectious disease forecasting into a re | (e.g., submarine). Research in this program will ogical markers as well as the analysis, correlation, and n technology infrastructure. Additionally, this program e effective predictive models of disease outbreak and able information, even when an individual has no    |         |           |         |
| FY 2019 Plans:  - Initiate additional clinical cohort studies that represent secondary transmis measurements.  - Evaluate performance of the minimal set of biomarkers for the ability to precohort data.  - Complete development of a prognostic assay that predicts contagiousness.  | edict contagiousness outcomes against the clinical  |         |           |         |
| FY 2019 to FY 2020 Increase/Decrease Statement: FY 2020 decrease reflects program completion.  |   |         |           |         |
| Title: Restoration of Brain Function Following Trauma  |   | 7.828   | -         |         |
| <b>Description:</b> The Restoration of Brain Function Following Trauma program modeling of brain activity and organization to develop approaches to treat trability to detect and quantify functional changes that occur in the human brait to correlate those changes with subsequent recall of those memories during developed neural interface hardware for monitoring and modulating neural a human clinical population. The ultimate goal was identification of efficacio recover the neural functions underlying memory, which are often disrupted a         | aumatic brain injury (TBI). Critical to success was the in during the formation of distinct new memories, and performance of behavioral tasks. This program also ictivity responsible for successful memory formation in us therapeutic approaches that could bypass and/or |         |           |         |
| Title: Autonomous Diagnostics to Enable Prevention and Therapeutics (ADE   | EPT)  | 2.500   | -         |         |
| <b>Description:</b> The overarching goal of the Autonomous Diagnostics to Enable to increase our ability to rapidly respond to a disease or threat and improve it by providing centralized laboratory capabilities at non-tertiary care settings. Acid (RNA)-based vaccines, potentially eliminating the time and labor require the same time improving efficacy. Additionally, ADEPT developed methods  | individual readiness and total force health protection ADEPT focused on the development of Ribonucleic ed for traditional manufacture of a vaccine while at   |         |           |         |

PE 0602115E: *BIOMEDICAL TECHNOLOGY* Defense Advanced Research Projects Agency

UNCLASSIFIED
Page 7 of 8

| Exhibit R-2, RDT&E Budget Item Justification: PB 2020 Defense Advanced | Research Projects Agency  | Date: March 2019 |
|--|---|------------------|
| 1  | R-1 Program Element (Number/Name) PE 0602115E I BIOMEDICAL TECHNOLOGY |                  |

| C. Accomplishments/Planned Programs (\$ in Millions)  | FY 2018 | FY 2019 | FY 2020 |
|---|---------|---------|---------|
| therapeutics, and kinetically control the timing and levels of gene expression so that these drugs will be safe and effective for use in healthy subjects. ADEPT also focused on advanced development of key elements for simple-to-operate diagnostic devices. |         |         |         |
| Accomplishments/Planned Programs Subtotals  | 88.962  | 101.300 | 97.771  |

#### D. Other Program Funding Summary (\$ in Millions)

N/A

Remarks

# E. Acquisition Strategy

N/A

#### F. Performance Metrics

Specific programmatic performance metrics are listed above in the program accomplishments and plans section.

PE 0602115E: *BIOMEDICAL TECHNOLOGY* Defense Advanced Research Projects Agency